Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) An aqueous formulation of a therapeutic agent comprising:

rapamycin in a pharmaceutically effective dosage;

ethanol in a residual concentration of 0.5 percent to less than two percent;

vitamin E TPGS; and

water, the rapamycin, vitamin E TPGS and water forming a stable aqueous solution, thereby remaining a solution without precipitation, the stable aqueous formulation comprising a final solution of rapamycin in the range from about 4 mg/ml to about 15 mg/ml~~, the aqueous formulation being a stable solution~~.

2. (Cancelled)

3. (Cancelled)

4. (Original) The liquid formulation according to claim 3, wherein the rapamycin comprises sirolimus.

5. (Original) The liquid formulation according to claim 3, wherein the rapamycin comprises CCI-779.

6. (Cancelled)

7. (Cancelled)

8. (Cancelled)

9. (Withdrawn) A method for the treatment of vascular disease comprising the administration of a liquid formulation of rapamycin proximate the disease site.

10. (Withdrawn) The method for the treatment of vascular disease according to claim 9, wherein the liquid formulation of rapamycin comprises rapamycin in a pharmaceutically effective dosage and one or more pharmaceutically acceptable solubility enhancers.